T. Gu

Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis

Q. Cheng, Jian Zhang, P. Luo, 2022, International journal of cancer.

TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Hui Meng, Jian Zhang, P. Luo, 2021, Frontiers in Immunology.

Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment

Jian Zhang, P. Luo, Xigang Hu, 2022, Journal of immunology research.

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database

Q. Cheng, Jian Zhang, P. Luo, 2023, EClinicalMedicine.

CACNA1C mutation as a prognosis predictor of immune checkpoint inhibitor in skin cutaneous melanoma.

Jian Zhang, P. Luo, Anqi Lin, 2023, Immunotherapy.

Reply to: Comments on “Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis”

Jian Zhang, P. Luo, Anqi Lin, 2023, International Journal of Cancer.

Correlation between IL3 signaling pathway-related genes and immune checkpoint inhibitor efficacy in patients with renal cell carcinoma.

Jian Zhang, P. Luo, Anqi Lin, 2023, Cancer biomarkers : section A of Disease markers.